Rexulti, a brexpiprazole oral tablet, has a recommended starting dosage of 0.5 mg once daily for seven days, which increases steadily to 2 milligrams after 15 days, according to a May 10 agency news release. The FDA granted fast-track designation for the drug.
“Agitation is one of the most common and challenging aspects of care among patients with dementia due to Alzheimer’s disease. ‘Agitation’ can include symptoms ranging from pacing or restlessness to verbal and physical aggression,” Tiffany Farchione, MD, director of the division of psychiatry in the FDA’s Center for Drug Evaluation and Research, said in the release. “These symptoms are leading causes of assisted living or nursing home placement and have been associated with accelerated disease progression.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
